



**Clinical trial results:**  
**Offline monitoring of parallel concentrations of intravenously administered anesthetics, opiates and relaxants in breath and in blood during anesthesia**  
**- a pilot study**

**Summary**

EudraCT number	2013-004127-36
Trial protocol	CZ
Global end of trial date	30 November 2014

**Results information**

Result version number	v1 (current)
This version publication date	12 August 2020
First version publication date	12 August 2020
Summary attachment (see zip file)	Summary (summary.docx)

**Trial information**

**Trial identification**

Sponsor protocol code	expir1
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Podřipská nemocnice s poliklinikou
Sponsor organisation address	Alej 17. listopadu 1101, Roudnice n.L., s.r.o, Czech Republic,
Public contact	Michal Kroupa, Podřipská nemocnice s poliklinikou, Roudnice n.L., s.r.o, mudrmichalkroupa@seznam.cz
Scientific contact	Michal Kroupa, Podřipská nemocnice s poliklinikou, Roudnice n.L., s.r.o, mudrmichalkroupa@seznam.cz

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	30 November 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	30 November 2014
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

pharmacokinetics

Protection of trial subjects:

Standard

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 February 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Czech Republic: 22
Worldwide total number of subjects	22
EEA total number of subjects	22

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	22
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

Number of subjects started	22
Number of subjects completed	22

### Period 1

Period 1 title	Main period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Main arm
-----------	----------

Arm description:

All drugs used and monitored in the study were administered SKH during general anesthesia at the planned procedure. Thus, it was administered independently of the study, in a standard manner common to general anesthesia and according to SPC. Due to the clinical study, the indication and dosage during anesthesia were not altered.

Therefore, in this pilot study, which aims to determine the relationship of concentration at certain (below) time intervals, no detailed characteristics and dosages of the substances were given. These are listed in the anesthesiology textbooks and in the SPC.

Arm type	Experimental
Investigational medicinal product name	Sufentanil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

inj. and 5 µg of sufentanil or 50 µg of sufentanil

Investigational medicinal product name	Propofol
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Amp. á 200mg, bottle. 500mg or 1000mg. Propofol

Investigational medicinal product name	Ultiva
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:	
inj. á 1mg, or 2mg, or Remifentanil á 1mg, 2mg, or 5mg remifentanil	
Investigational medicinal product name	Rocuronium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details:	
inj. 50mg rocuronium	

<b>Number of subjects in period 1</b>	Main arm
Started	22
Completed	22

## Baseline characteristics

### Reporting groups

Reporting group title	Main period
Reporting group description: -	

Reporting group values	Main period	Total	
Number of subjects	22	22	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	22	22	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	19	19	
Male	3	3	

### Subject analysis sets

Subject analysis set title	Population selection
Subject analysis set type	Full analysis

Subject analysis set description:

The study included SKH with ASA 1-2 aged 18-65 years, undergoing a planned operation of at least 30 min, where the use of any of these substances was expected. As this was a pilot study with the assumption of limited choice of SKH (small hospital with limited surgery), no other selection criterion was chosen, nor was there an effort for gender parity (a large part of SKH was anesthetized for gynecological performance and therefore in the study was the prevalence of women). A prerequisite for this was the consent of SKH to conduct the study.

Reporting group values	Population selection		
Number of subjects	22		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		

From 65-84 years	22		
85 years and over	0		

Gender categorical			
Units: Subjects			
Female	19		
Male	3		

## End points

### End points reporting groups

Reporting group title	Main arm
-----------------------	----------

Reporting group description:

All drugs used and monitored in the study were administered SKH during general anesthesia at the planned procedure. Thus, it was administered independently of the study, in a standard manner common to general anesthesia and according to SPC. Due to the clinical study, the indication and dosage during anesthesia were not altered.

Therefore, in this pilot study, which aims to determine the relationship of concentration at certain (below) time intervals, no detailed characteristics and dosages of the substances were given. These are listed in the anesthesiology textbooks and in the SPC.

Subject analysis set title	Population selection
Subject analysis set type	Full analysis

Subject analysis set description:

The study included SKH with ASA 1-2 aged 18-65 years, undergoing a planned operation of at least 30 min, where the use of any of these substances was expected. As this was a pilot study with the assumption of limited choice of SKH (small hospital with limited surgery), no other selection criterion was chosen, nor was there an effort for gender parity (a large part of SKH was anesthetized for gynecological performance and therefore in the study was the prevalence of women). A prerequisite for this was the consent of SKH to conduct the study.

### Primary: Main end point

End point title	Main end point <sup>[1]</sup>
-----------------	-------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

150 min

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There was no comparison conducted, only one data set

<b>End point values</b>	Main arm			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: concentration mug/l				
number (not applicable)	1			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

None

Assessment type	Non-systematic
-----------------	----------------

---

### Dictionary used

---

Dictionary name	MedDRA
-----------------	--------

---

Dictionary version	23
--------------------	----

---

Frequency threshold for reporting non-serious adverse events: 1 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: There were no experimental drugs administered, only standard anesthetics. Their concentration in breath was observed.



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported